ClinicalTrials.gg
CompletedNCT05076838Updated Oct 20, 2026Results posted

Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy

A Phase 1/2 interventional study of Diazepam Nasal Spray [Valtoco] in Epilepsy, sponsored by Neurelis, Inc.. Completed at 13 sites in United States. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Neurelis, Inc. · Phase 1/2, Interventional, and Treatment

Updated Oct 20, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing diazepam in Epilepsy — none open to participants now, none under way, none of them phase 3. Diazepam · Epilepsy.

Enrollment
7th of 10
36 · median 68
Started
2021
the only one that year
Phase 1/2
2 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
3 of 10
Neurelis, Inc.

Among the 10 studies testing diazepam in Epilepsy, this one is the 7th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1/2, and was the 9th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

None of the 10 studies testing diazepam in Epilepsy is open now. The open studies under Epilepsy, anywhere →

Where they have run

About diazepam

Diazepam: first FDA approval 1963 (VALIUM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing diazepam in Epilepsy as a file.
02

Study summary

This is a Phase 1/2a, open-label, single-dose, PK study of VALTOCO with open-label safety period in pediatric epilepsy subjects age 2 to 5 years.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a clinical diagnosis of epilepsy and, in the opinion of the Investigator, may need benzodiazepine intervention for seizure control.
  • Subjects having either partial or generalized epilepsy with motor seizures or seizures with clear alteration of awareness, for which rescue medications have been used at least once in the last 3 months or in the opinion of the investigator, may need a benzodiazepine intervention for seizure control 1-2 times every 3 months on average.

Exclusion criteria

Exclusion Criteria:

  • Subjects whose body weight are \< 6 kg or > 33 kg.
  • Subject is undergoing intracranial electroencephalogram (EEG) monitoring.
  • In the opinion of the investigator, a history of medical history that would jeopardize the safety of the subject or impact the validity of the study results (such as significant gastrointestinal, renal, nasal polyps or any nasal passage abnormality that could interfere with nasal spray administration.
  • Subject has had significant traumatic injury, major surgery or open within 30 days prior to study screening.
  • Participation in a clinical trial within 30 days prior to the first dose of study drug.
  • Inadequate or difficult venous access that may jeopardize the quality or timing of the PK samples.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Valtoco In Pediatric Subjects with Epilepsy

    5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.

    Drug: Diazepam Nasal Spray [Valtoco]

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of Diazepam After Intranasal VALTOCO Administered to Subjects With Epilepsy 2 to 5 Years of Age

    Pharmacokinetic levels of diazepam

    Time frame: 0-6 hours

07

Results

Posted Sep 22, 2026

Participant flow

Participant flow — Overall Study
MilestoneValtoco In Pediatric Subjects With Epilepsy
Started36
Valtoco 10mg29
Valtoco 5mg3
Valtoco 15mg4
Completed31
Not completed5

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax) of Diazepam After Intranasal VALTOCO Administered to Subjects With Epilepsy 2 to 5 Years of Age

Pharmacokinetic levels of diazepam

Time frame:
0-6 hours
Reported as:
Mean · Cmax (ng/ml)
Maximum Plasma Concentration (Cmax) of Diazepam After Intranasal VALTOCO Administered to Subjects With Epilepsy 2 to 5 Years of Age
Cmax (ng/ml)Valtoco 5mg 2 to 3 Years OldValtoco 10mg 2 to 3 Years OldValtoco 10mg 4 to 5 Years OldValtoco 15mg 4 to 5 Years Old
Maximum Plasma Concentration (Cmax) of Diazepam After Intranasal VALTOCO Administered to Subjects With Epilepsy 2 to 5 Years of Age94.34 ± 60.29269.25 ± 258.77279.91 ± 198.58243.07 ± 249.44

Adverse events

Collected over 180 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valtoco 5mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Valtoco 10mg0/29 (0%)6/29 (20.7%)18/29 (62.1%)
Valtoco 15mg0/4 (0%)2/4 (50%)3/4 (75%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventValtoco 5mgValtoco 10mgValtoco 15mg
HypoxiaRespiratory, thoracic and mediastinal disorders1/30/290/4
PneumoniaInfections and infestations1/30/290/4
SeizureNervous system disorders0/32/291/4
pneumothoraxRespiratory, thoracic and mediastinal disorders0/30/291/4
urinary retentionRenal and urinary disorders0/30/291/4
EpilepsyNervous system disorders0/32/290/4
status epilepticusNervous system disorders0/31/290/4
respiratory depressionRespiratory, thoracic and mediastinal disorders0/31/290/4
pneumonia aspirationInfections and infestations0/31/290/4
anaemiaBlood and lymphatic system disorders0/31/290/4
Most frequent other events
Showing 10 of 27
Most frequent other events
EventValtoco 5mgValtoco 10mgValtoco 15mg
PyrexiaGeneral disorders3/34/291/4
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/36/291/4
nasal congestionRespiratory, thoracic and mediastinal disorders1/31/290/4
hypoxiaRespiratory, thoracic and mediastinal disorders1/30/290/4
Nasal OedemaRespiratory, thoracic and mediastinal disorders1/30/290/4
InfluenzaInfections and infestations1/31/290/4
Gastroenteritis NorovirusInfections and infestations1/30/290/4
PneumoniaInfections and infestations1/30/290/4
SeizureNervous system disorders1/32/291/4
VomitingGastrointestinal disorders1/31/290/4

Baseline characteristics

Age, Customized
Age, Customized(participants)Valtoco In Pediatric Subjects With Epilepsy
2 to 3 years19
4 to 5 years17
Sex: Female, Male
Sex: Female, Male(Participants)Valtoco In Pediatric Subjects With Epilepsy
Female15
Male21
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Valtoco In Pediatric Subjects With Epilepsy
Hispanic or Latino17
Not Hispanic or Latino19
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Valtoco In Pediatric Subjects With Epilepsy
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White26
More than one race3
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)Valtoco In Pediatric Subjects With Epilepsy
United States36
08

Study locations

13 sites
  • Northwest Florida Clinical Research Group, LLC.
    Gulf Breeze, Florida 32561, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • AdventHealth Research Institute
    Orlando, Florida 32803, United States
  • Center for Rare Neurological Diseases
    Norcross, Georgia 30093, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Missouri Women & Children's Hospital
    Columbia, Missouri 65201, United States
  • Northeast Regional Epilepsy Group
    Hackensack, New Jersey 07601, United States
  • Boston Children's Health Physicians
    Hawthorne, New York 10532, United States
  • University of Rochester
    Rochester, New York 14623, United States
  • Duke University Hospital
    Durham, North Carolina 27710, United States
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38105, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75225, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
09

References and documents

Publications

  • Segal EB, Wheless JW, Zafar M, Shih EK, Ngo LY, Carrazana E, Rabinowicz AL; DIAZ.001.008 Study Group. Pharmacokinetics and 180-day safety of diazepam nasal spray in pediatric patients with epilepsy aged 2-5 years. Epilepsia. 2025 Sep;66(9):3231-3241. doi: 10.1111/epi.18473. Epub 2025 Jul 12. PubMed 40650667 ↗
  • Segal EB, Wheless JW, Wolf SM, Zafar M, Renfroe JB, Lopez-Toledano MA, Ngo LY, Rabinowicz AL, Carrazana E. Safety and Local Tolerability of Diazepam Nasal Spray for Children With Epilepsy Aged 2-5 Years: Final Results of a Phase 1/2a Trial. J Child Neurol. 2026 Aug 26:8830738261474614. doi: 10.1177/08830738261474614. Online ahead of print. PubMed 42647177 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Mar 2025, 40 months.

Results were first posted in Sep 2026, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2021
First posted
Oct 13, 2021
StartActual
Nov 8, 2021
Primary completionActual
Mar 11, 2025
CompletionActual
Mar 11, 2025
Results first posted
Sep 22, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Posted results revised
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05076838
Lead sponsor
Neurelis, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2021
Start date
Nov 8, 2021
Primary completion
Mar 11, 2025
Completion
Mar 11, 2025
Results posted
Sep 22, 2026
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion